In vivo fate of lipid-based nanoparticles

被引：67
|
作者：
Qi, Jianping [1 ]
Zhuang, Jie [2 ]
Lu, Yi [1 ]
Dong, Xiaochun [1 ]
Zhao, Weili [1 ,3 ]
Wu, Wei [1 ]
机构：
[1] Fudan Univ, Sch Pharm, Key Lab Smart Drug Delivery MOE & PLA, Shanghai, Peoples R China
[2] Shanghai Univ Med & Hlth Sci, Sch Pharm, Shanghai, Peoples R China
[3] Henan Univ, Key Lab Special Funct Mat, Minist Educ, Kaifeng, Peoples R China
来源：
DRUG DISCOVERY TODAY | 2017年 / 22卷 / 01期
基金：
中国国家自然科学基金;
关键词：
ORAL BIOAVAILABILITY; DELIVERY-SYSTEM; SIRNA DELIVERY; DRUG-DELIVERY; PARTICLE-SIZE; CHAIN-LENGTH; CARRIERS NLC; BIODISTRIBUTION; ABSORPTION; FORMULATIONS;
D O I：
10.1016/j.drudis.2016.09.024
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The in vivo fate of lipid-based nanoparticles (LBNs) is essentially determined by the properties of their lipid compositions. LBNs are rapidly degraded via lipolysis wherever lipases are abundant, especially in the gastrointestinal tract. LBNs that survive lipolysis can be translocated through the circulation to reach terminal organs or tissues. Lipid composition, particle size, and surface decoration, as well as the formation of protein corona, are the main factors influencing the in vivo fate of LBNs. As we discuss here, elucidation of the in vivo fate of LBNs helps weigh the balance between lipolysis and biorecognition, and is emerging as a new field of research.
引用
收藏
页码：166 / 172
页数：7
相关论文
共 50 条
  • [41] Recent advances in siRNA delivery mediated by lipid-based nanoparticles
    Yonezawa, Sei
    Koide, Hiroyuki
    Asai, Tomohiro
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2020, 154 : 64 - 78
  • [42] Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes
    Wayteck, Laura
    Dewitte, Heleen
    De Backer, Lynn
    Breckpot, Karine
    Demeester, Jo
    De Smedt, Stefaan C.
    Raemdonck, Koen
    [J]. BIOMATERIALS, 2016, 77 : 243 - 254
  • [43] Lipid-based nanoparticles as drug delivery carriers for cancer therapy
    Waheed, Ibtesam
    Ali, Anwar
    Tabassum, Huma
    Khatoon, Narjis
    Lai, Wing-Fu
    Zhou, Xin
    [J]. FRONTIERS IN ONCOLOGY, 2024, 14
  • [44] Design of lipid-based nanoparticles for delivery of therapeutic nucleic acids
    Mendonca, Monique C. P.
    Kont, Ayse
    Kowalski, Piotr S.
    O'Driscoll, Caitriona M.
    [J]. DRUG DISCOVERY TODAY, 2023, 28 (03) : 1 - 17
  • [45] Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy
    Hao, Yang
    Ji, Zhonghao
    Zhou, Hengzong
    Wu, Dongrun
    Gu, Zili
    Wang, Dongxu
    ten Dijke, Peter
    [J]. MEDCOMM, 2023, 4 (04):
  • [46] Immunotoxicity derived from manipulating leukocytes with lipid-based nanoparticles
    Peer, Dan
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (15) : 1738 - 1748
  • [47] A Concise Review on Effect of PEGylation on the Properties of Lipid-Based Nanoparticles
    Krishnan, Janesha
    Poomalai, Praveena
    Ravichandran, Ashwin
    Reddy, Aishwarya
    Sureshkumar, Raman
    [J]. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2024, 22 (05) : 246 - 264
  • [48] Cationic and anionic lipid-based nanoparticles in CEC for protein separation
    Nilsson, Christian
    Harwigsson, Ian
    Birnbaum, Staffan
    Nilsson, Staffan
    [J]. ELECTROPHORESIS, 2010, 31 (11) : 1773 - 1779
  • [49] Development of Lipid-Based Nanoparticles for Enhancing the Oral Bioavailability of Paclitaxel
    Pandita, Deepti
    Ahuja, Alka
    Lather, Viney
    Benjamin, Biju
    Dutta, Tathagata
    Velpandian, Thirumurthy
    Khar, Roop Krishen
    [J]. AAPS PHARMSCITECH, 2011, 12 (02): : 712 - 722
  • [50] Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib
    Korani, Mitra
    Korani, Shahla
    Zendehdel, Elham
    Jaafari, Mahmoud R.
    Sathyapalan, Thozhukat
    Sahebkar, Amirhossein
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2020, 20 (06) : 643 - 650
12345